351 related articles for article (PubMed ID: 26332238)
41. Pulmonary Madurella mycetomatis mycetoma secondary to knee eumycetoma, Senegal.
Diongue K; Diallo MA; Sarr L; Seck MC; Bréchard L; Ndiaye M; Badiane AS; Ranque S; Ndiaye D
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009238. PubMed ID: 33764976
[TBL] [Abstract][Full Text] [Related]
42. Madurella mycetomatis mycetoma treated successfully with oral posaconazole.
Difonzo EM; Massi D; Vanzi L; Lotti L; Agnoletti AF; Baldinotti V
J Chemother; 2011 Aug; 23(4):243-4. PubMed ID: 21803706
[No Abstract] [Full Text] [Related]
43. A Madurella mycetomatis Grain Model in Galleria mellonella Larvae.
Kloezen W; van Helvert-van Poppel M; Fahal AH; van de Sande WW
PLoS Negl Trop Dis; 2015; 9(7):e0003926. PubMed ID: 26173126
[TBL] [Abstract][Full Text] [Related]
44. Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan.
Fahal A; Mahgoub el S; El Hassan AM; Abdel-Rahman ME
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003679. PubMed ID: 25816316
[TBL] [Abstract][Full Text] [Related]
45. Antifungal Activity of Natural Naphthoquinones and Anthraquinones against Madurella mycetomatis.
Ma J; Todd M; van de Sande WWJ; Biersack B
Chem Biodivers; 2023 May; 20(5):e202300151. PubMed ID: 37067830
[TBL] [Abstract][Full Text] [Related]
46. Comparing the performance of the common used eumycetoma diagnostic tests.
Siddig EE; Nyuykonge B; Mhmoud NA; Abdallah OB; Bahar MEN; Ahmed ES; Nyaoke B; Zijlstra EE; Verbon A; Bakhiet SM; Fahal AH; van de Sande WWJ
Mycoses; 2023 May; 66(5):420-429. PubMed ID: 36583225
[TBL] [Abstract][Full Text] [Related]
47. Potential utility of random amplified polymorphic DNA (RAPD) and restriction endonuclease assay (REA) as typing systems for Madurella mycetomatis.
Lopes MM; Freitas G; Boiron P
Curr Microbiol; 2000 Jan; 40(1):1-5. PubMed ID: 10568795
[TBL] [Abstract][Full Text] [Related]
48. Madura's foot: report of a case caused by Madurella mycetomatis.
Verdolini R; Amerio P; Bugatti L; Manso E; Cataldi I; Brancorsini D; Nicolini M; Filosa G; Giangioacomi M
Eur J Dermatol; 2000 Dec; 10(8):627-9. PubMed ID: 11125328
[TBL] [Abstract][Full Text] [Related]
49. Review of 21 cases of mycetoma from 1991 to 2014 in Rio de Janeiro, Brazil.
Sampaio FM; Wanke B; Freitas DF; Coelho JM; Galhardo MC; Lyra MR; Lourenço MC; Paes RA; do Valle AC
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005301. PubMed ID: 28192433
[TBL] [Abstract][Full Text] [Related]
50. Novel Compound MMV1804559 from the Global Health Priority Box Exhibits In Vitro and In Vivo Activity against
Ma J; Eadie K; Schippers M; Fahal A; Laleu B; Verbon A; van de Sande WWJ
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892422
[TBL] [Abstract][Full Text] [Related]
51. A murine model of Madurella mycetomatis eumycetoma.
Ahmed AO; van Vianen W; ten Kate MT; van de Sande WW; van Belkum A; Fahal AH; Verbrugh HA; Bakker-Woudenberg IA
FEMS Immunol Med Microbiol; 2003 Jun; 37(1):29-36. PubMed ID: 12770757
[TBL] [Abstract][Full Text] [Related]
52. Proteomic analysis of the processes leading to Madurella mycetomatis grain formation in Galleria mellonella larvae.
Sheehan G; Konings M; Lim W; Fahal A; Kavanagh K; van de Sande WWJ
PLoS Negl Trop Dis; 2020 Apr; 14(4):e0008190. PubMed ID: 32267851
[TBL] [Abstract][Full Text] [Related]
53. Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.
Lim W; Konings M; Parel F; Eadie K; Strepis N; Fahal A; Verbon A; van de Sande WWJ
Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35064672
[TBL] [Abstract][Full Text] [Related]
54. Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit.
Seibold MA; Donnelly S; Solon M; Innes A; Woodruff PG; Boot RG; Burchard EG; Fahy JV
J Allergy Clin Immunol; 2008 Nov; 122(5):944-950.e3. PubMed ID: 18845328
[TBL] [Abstract][Full Text] [Related]
55. Challenges in culture-negative cases of Madurella mycetomatis: A case report re-accentuating PCR as an essential diagnostic tool.
K S; Das S; Pandhi D; Rai G; Ansari MA; Gupta C; Haque S; Dar SA
J Mycol Med; 2017 Dec; 27(4):577-581. PubMed ID: 29102309
[TBL] [Abstract][Full Text] [Related]
56. Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma.
Nyuykonge B; Siddig EE; Mhmoud NA; Nyaoke BA; Zijlstra EE; Verbon A; Bakhiet S; Fahal AH; van de Sande WWJ
Mycoses; 2022 Dec; 65(12):1170-1178. PubMed ID: 36005544
[TBL] [Abstract][Full Text] [Related]
57. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.
Lim W; Eadie K; Konings M; Rijnders B; Fahal AH; Oliver JD; Birch M; Verbon A; van de Sande W
J Antimicrob Chemother; 2020 Apr; 75(4):936-941. PubMed ID: 31904836
[TBL] [Abstract][Full Text] [Related]
58. Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility.
van de Sande WW; Fahal A; Verbrugh H; van Belkum A
J Immunol; 2007 Sep; 179(5):3065-74. PubMed ID: 17709521
[TBL] [Abstract][Full Text] [Related]
59. Use of immunoblotting in testing Madurella mycetomatis specific antigen.
ELbadawi HS; Mahgoub E; Mahmoud N; Fahal AH
Trans R Soc Trop Med Hyg; 2016 May; 110(5):312-6. PubMed ID: 27198216
[TBL] [Abstract][Full Text] [Related]
60. Madurella mycetomatis as an agent of brain abscess: case report and review of literature.
Mir F; Shakoor S; Khan MJ; Minhas K; Zafar A; Zaidi AK
Mycopathologia; 2013 Dec; 176(5-6):429-34. PubMed ID: 24085615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
